Bristol Myers Squibb announced that the European Medicines Agency (EMA) validated its Type II variation application for Opdivo® (nivolumab) plu...
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to ...
Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell thera...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigim...
Integrated DNA Technologies (IDT), a global leader in CRISPR genome editing solutions, inked a licensing agreement with SeQure Dx, a company focused on off...
Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related di...
Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced that it has receive...
Senhwa Biosciences, Inc. (TPEx: 6492), announced IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with c...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is proud to announce its partnership with the National Cancer Institute (...
Clinical evaluation of several modified release once-daily formulations of danuglipron resulted in encouraging pharmacokinetic data for several candi...
BioArctic AB is pleased to announce that its partner, Eisai, has received approval from the Department of Health in Hong Kong for Leqembi® (bra...
Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Pa...
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application f...
© 2025 Biopharma Boardroom. All Rights Reserved.
